A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer

Heregulins (HRGs) bind to the receptors HER3 or HER4, induce receptor dimerization, and trigger downstream signaling that leads to tumor progression and resistance to targeted therapies. Increased expression of HRGs has been associated with worse clinical prognosis; therefore, attempts to block HRG-...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Mota, Jose Mauricio, Collier, Katharine Ann, Barros Costa, Ricardo Lima, Taxter, Timothy, Kalyan, Aparna, Leite, Caio A., Chae, Young Kwang, Giles, Francis J., Carneiro, Benedito A.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5687690/
https://ncbi.nlm.nih.gov/pubmed/29179520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18467
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki